

Claims

1.-11. (canceled)

12. (currently amended) A substantially pure or isolated stabilized oligodeoxynucleotide of between 18 and 30 nucleotides in length~~The stabilized oligodeoxynucleotide of claim 8~~, comprising any one of

5'-[X₁X₂]TGCATCGATGCAGGGGGG -3' (SEQ ID NO:12);
5'- [X₁X₂]TGCACCGGTGCAGGGGGG -3' (SEQ ID NO:13);
5'- [X₁X₂]TGCGTCGACGCAGGGGGG -3' (SEQ ID NO:14);
5'- [X₁X₂]TGCGCCGGCGCAGGGGGG -3' (SEQ ID NO:17);
5'- GGTGCATCGATGCAGGGGGG -3' (SEQ ID NO: 1);
5'- GGTGCGTCGACGCAGGGGGG -3' (SEQ ID NO: 31);
5'- GGTGCACCGGTGCAGGGGGG -3' (SEQ ID NO: 2); or,
5'- GGTGCATCGATGCAGGGGGG -3' (SEQ ID NO: 73).

13. (currently amended) The stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, wherein the oligodeoxynucleotide is modified to prevent degradation.

14. (currently amended) The stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, wherein the oligodeoxynucleotide has a phosphate backbone modification.

15. (previously presented) The stabilized oligodeoxynucleotide of claim 14, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

16.-18. (canceled)

19. (currently amended) An oligodeoxynucleotide delivery complex comprising the stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, and a targeting moiety.

20. (previously presented) The stabilized oligodeoxynucleotide delivery complex of claim 19, wherein the targeting moiety is selected from the group consisting of a cholesterol, a virosome, a liposome, a lipid, and a target cell specific binding agent.

21. **(previously presented)** The oligodeoxynucleotide delivery complex of claim 19, wherein the stabilized oligodeoxynucleotide and the targeting moiety are covalently linked.

22. **(currently amended)** A pharmacological composition comprising the stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, and a pharmacologically acceptable carrier.

23.-60. **(canceled)**

61. **(currently amended)** The stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, wherein the stabilized oligonucleotide comprises at least one~~Pu₁Py₂CpG Pu₃Py₄ comprise~~ phosphodiester base[[s]].

62. **(currently amended)** The stabilized oligodeoxynucleotide of claim 61, wherein the stabilized oligonucleotide comprises a plurality of~~Pu₁Py₂CpG Pu₃Py₄ are~~ phosphodiester bases.

63. **(canceled)**

64. **(currently amended)** The stabilized oligodeoxynucleotide of claim 61, wherein the stabilized oligonucleotide~~X₁X₂X₃~~ comprises one or more phosphorothioate bases.

65. **(currently amended)** The stabilized oligodeoxynucleotide of claim 61, wherein the stabilized oligonucleotide~~X₄X₅X₆(W)_M(G)_N~~ comprises a plurality of~~one or more~~ phosphorothioate bases.

66. **(Canceled)**

67. **(currently amended)** The stabilized oligodeoxynucleotide of claim ~~[[66]]~~12, further comprising at least one additional G in the 5' far flanking region.